Summary

Global Enzyme Inhibitors Market is valued approximately at USD 180.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.53% over the forecast period 2024-2032. Enzyme inhibitors are molecules that impede the function of enzymes, which are proteins responsible for accelerating biochemical reactions in living organisms. These inhibitors can attach to enzymes, disrupting their activity either temporarily or permanently. They function through various mechanisms, such as obstructing the enzyme's active site, changing its structure, or blocking substrate binding. Enzyme inhibitors play crucial roles in several domains, including medicine (as drugs), agriculture (as pesticides), and biochemistry (for investigating enzyme functions). They are used to regulate biological processes, treat diseases, and understand enzyme kinetics and mechanisms. The rising focus on targeted therapies and precision medicine is a key trend that is primarily supporting the growth of the Global Enzyme Inhibitors Market during the estimated period. Enzyme inhibitors, which selectively target and limit the activity of particular enzymes associated with illnesses including cancer, inflammatory disorders, and metabolic problems, have been developed by pharmaceutical firms and researchers at an increasing rate. This trend is fueled by developments in drug discovery, genetics, and molecular biology that make it possible to identify important enzyme targets and provide more individualized and effective therapies.

The market has witnessed a substantial expansion due to outsourced manufacturing and the development of precise and effective treatments for chronic illnesses like cancer and respiratory diseases. Also, supportive regulatory frameworks and initiatives aimed at accelerating drug development and approval processes are encouraging investment and innovation in the enzyme inhibitors market. Along with this, the growing demand for precise and efficient medications, as well as an increase in diseases such as cancer, and the expanding global activities in agriculture and pharmaceuticals are the key factors that are attributing to the demand of enzyme inhibitors globally. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded worldwide, which is projected to rise and is likely to reach 30.2 million new cases by 2040. Cancer is as an intricate multifaceted disease, arises from various physiological and biochemical changes. Cancer cells often develop resistance to traditional anticancer drugs, leading to relapse. Therefore, the continuous research for novel and potent anticancer medications is anticipated to boost the demand for enzyme inhibitors, in turn, propel market growth. However, patent expirations of enzyme inhibitor drugs and the accessibility of affordable generic alternatives are likely to stifle market growth between 2022 and 2032.

The key regions considered for the global Enzyme Inhibitors Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue. The expansion of the North American market is fueled by various factors, such as a robust healthcare infrastructure and enhanced government initiatives with favorable reimbursement policies. Moreover, the increasing prevalence of cancer is propelling the growth of the enzyme inhibitors market in the region. According to the Canadian Cancer Statistics 2021 report, cancer remains the primary cause of death in Canada. Approximately 2 in 5 Canadians are projected to receive a cancer diagnosis during their lifetime, and about 1 in 4 will succumb to the disease. In 2021, an estimated 229,200 Canadians will receive a cancer diagnosis, leading to approximately 84,600 cancer-related deaths. Lung, breast, colorectal, and prostate cancers are anticipated to remain the most prevalent diagnoses, comprising 46% of all cases in 2021. The top three causes of cancer-related deaths in 2021 are expected to be lung cancer (25%), colorectal cancer (11%), and pancreatic cancer (7%). As a result, the rising incidence of cancer in North America is expected to have a major impact on the growth of the market. Whereas, the market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:
Abbott Laboratories
Amgen Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb
Cipla Inc
F. Hoffmann-La Roche
Novartis AG
Pfizer Inc.

The detailed segments and sub-segment of the market are explained below:

By Type
Proton Pump Inhibitors [PPIs]
Protease Inhibitors
Reverse Transcriptase Inhibitors
Kinase Inhibitors
Other Types

By Application
Medical
Agriculture
Other Applications


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Global Enzyme Inhibitors Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Global Enzyme Inhibitors Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Type
2.3.2. By Application
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Global Enzyme Inhibitors Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Global Enzyme Inhibitors Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Enzyme Inhibitors Market Size & Forecasts by Type 2022-2032
5.1. Proton Pump Inhibitors [PPIs]
5.2. Protease Inhibitors
5.3. Reverse Transcriptase Inhibitors
5.4. Kinase Inhibitors
5.5. Other Types
Chapter 6. Global Enzyme Inhibitors Market Size & Forecasts by Application 2022-2032
6.1. Medical
6.2. Agriculture
6.3. Other Applications
Chapter 7. Global Enzyme Inhibitors Market Size & Forecasts by Region 2022-2032
7.1. North America Enzyme Inhibitors Market
7.1.1. U.S. Enzyme Inhibitors Market
7.1.1.1. Type breakdown size & forecasts, 2022-2032
7.1.1.2. Application breakdown size & forecasts, 2022-2032
7.1.2. Canada Enzyme Inhibitors Market
7.2. Europe Enzyme Inhibitors Market
7.2.1. U.K. Enzyme Inhibitors Market
7.2.2. Germany Enzyme Inhibitors Market
7.2.3. France Enzyme Inhibitors Market
7.2.4. Spain Enzyme Inhibitors Market
7.2.5. Italy Enzyme Inhibitors Market
7.2.6. Rest of Europe Enzyme Inhibitors Market
7.3. Asia-Pacific Enzyme Inhibitors Market
7.3.1. China Enzyme Inhibitors Market
7.3.2. India Enzyme Inhibitors Market
7.3.3. Japan Enzyme Inhibitors Market
7.3.4. Australia Enzyme Inhibitors Market
7.3.5. South Korea Enzyme Inhibitors Market
7.3.6. Rest of Asia Pacific Enzyme Inhibitors Market
7.4. Latin America Enzyme Inhibitors Market
7.4.1. Brazil Enzyme Inhibitors Market
7.4.2. Mexico Enzyme Inhibitors Market
7.4.3. Rest of Latin America Enzyme Inhibitors Market
7.5. Middle East & Africa Enzyme Inhibitors Market
7.5.1. Saudi Arabia Enzyme Inhibitors Market
7.5.2. South Africa Enzyme Inhibitors Market
7.5.3. Rest of Middle East & Africa Enzyme Inhibitors Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Amgen Inc.
8.3.3. AstraZeneca PLC
8.3.4. Bayer AG
8.3.5. Boehringer Ingelheim International GmbH
8.3.6. Bristol-Myers Squibb
8.3.7. Cipla Inc.
8.3.8. F. Hoffmann-La Roche
8.3.9. Novartis AG
8.3.10. Pfizer Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes